Among patients treated with preferred DAAs, cirrhosis, HBV coinfection, BMI ≥25, HbA1c ≥ 6.5, HOMA index ≥2, triglyceride ≥150 mg/dl, the use of sofosbuvir-based or EBR/GZR regimens, pre-therapy ALT ≥1xULN, higher AST, AFP, T-Bil, and lower albumin level was found (Liu et al., 2020). This evidence concerns the gene ALB and Cirrhosis.